In a filing, Harmony Biosciences Holdings Inc revealed its CHIEF COMMERCIAL OFFICER Dierks Jeffrey unloaded Company’s shares for reported $0.16 million on Mar 03 ’25. In the deal valued at $32.67 per share,4,869 shares were sold. As a result of this transaction, Dierks Jeffrey now holds 0 shares worth roughly $0.0.
Then, JEFFREY G DIERKS bought 4,869 shares, generating $164,816 in total proceeds.
Before that, Dierks Jeffrey sold 13,125 shares. Harmony Biosciences Holdings Inc shares valued at $489,634 were divested by the CHIEF COMMERCIAL OFFICER at a price of $37.31 per share. As a result of the transaction, Dierks Jeffrey now holds 0 shares, worth roughly $0.0.
Deutsche Bank initiated its Harmony Biosciences Holdings Inc [HRMY] rating to a Buy in a research note published on February 11, 2025; the price target was $55. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. UBS started covering the stock on September 10, 2024. It rated HRMY as “a Buy”.
Price Performance Review of HRMY
On Friday, Harmony Biosciences Holdings Inc [NASDAQ:HRMY] saw its stock fall -0.12% to $33.67. Over the last five days, the stock has lost -0.53%. Harmony Biosciences Holdings Inc shares have fallen nearly -2.15% since the year began. Nevertheless, the stocks have risen 9.50% over the past one year. While a 52-week high of $41.61 was reached on 01/21/25, a 52-week low of $28.14 was recorded on 03/04/25. SMA at 50 days reached $36.33, while 200 days put it at $34.46.
Levels Of Support And Resistance For HRMY Stock
The 24-hour chart illustrates a support level at 33.28, which if violated will result in even more drops to 32.89. On the upside, there is a resistance level at 34.35. A further resistance level may holdings at 35.02. The Relative Strength Index (RSI) on the 14-day chart is 42.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.65, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.03%. Stochastics %K at 24.58% indicates the stock is a holding.
The most recent change occurred on June 21, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $48 price target.
